@evosep.bsky.socialBetter analytical workflows can help bring new therapies to patients faster. At #CASSS, we’re discussing how robust, standardized LC-MS #proteomics can improve reproducibility, scalability, and efficiency across #biopharma R&D. Stop by and meet the Evosep team!
@newsen.bsky.socialZifo to Showcase Future of Scientific Research at Lab of the Future Europe 2026 #None #Amsterdam #Biopharma #Zifo #Lab_of_the_Future
@nikolospharma.bsky.social
@outsourcedpharma.bsky.socialWhat if AI’s best regulatory use isn’t writing your submission, but finding the weaknesses before FDA does?
In this clip from The Outsourcing Advisor, Bikash Chatterjee explains why AI may be most valuable as a stress test, not just a writing tool. shorturl.at/nbpSo
#AI #FDA #Biopharma #Outsourcing
@leeasplund.bsky.socialWelcome to Wednesday Words, where I will define one word used in biotechnology or biopharma each Wednesday morning!
If you want to learn more, check out: sbee.link/v8nbc6rhqt
@qorvis.bsky.socialChina’s bet on biotechnology is paying off faster than expected.
What does this rise mean for patients, governments, biotech companies, and investors?
Read more: qorvis.com/what-chinas-...
@oni-bio.bsky.socialWe’re here at #DDFSummit2026 in Boston! 🔬
Stop by and chat with the ONI team about how super-resolution microscopy can provide deeper insight into LNPs at the single-particle level.
📊 Don’t miss our poster on LNP characterization!
@nikolospharma.bsky.social
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) receives FDA clearance for a Phase 2 trial of Lucid-MS, a first-in-class drug designed to rebuild the myelin sheath rather than suppress the immune system — a potential breakthrough in MS treatment. #MultipleSclerosis #Biopharma
@drtimos.bsky.social💉 Vaccines & Infectious Diseases 🦠
#LucidQuest equips BioPharma & investors with real-time insights to outpace the curve.
📩 [email protected] or http://dlvr.it/TVQSfY
#Vaccines #InfectiousDiseases #BioPharma #DueDiligence #LifeScienceStrategy
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) secures FDA clearance for a Phase 2 trial of Lucid-MS, a first-in-class drug targeting demyelination in multiple sclerosis patients. Rodman & Renshaw initiates coverage with a Buy rating and $8 price target. #MultipleSclerosis #Biopharma
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) receives FDA clearance for its Lucid-MS IND application, paving the way for a phase 2 trial of a first-in-class MS drug targeting demyelination directly rather than suppressing the immune system. #Biopharma #MultipleSclerosis
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) receives FDA IND clearance and advances Lucid-MS into a Phase 2 trial for multiple sclerosis. The first-in-class PAD2 inhibitor targets demyelination directly, not immune suppression. #MultipleSclerosis #Biopharma
@newsramp.comSilo Pharma (NASDAQ: SILO) will present its nose-to-brain SPC-15 PTSD therapy at the IPAC-RS 2026 Nasal Innovation Forum in Jersey City this September. Preclinical stability data continues to support the program's advancement. #Biopharma #PTSD
@newsramp.comKairos Pharma ($KAPA) CEO John Yu, MD, will present at the H.C. Wainwright 28th Annual Global Investment Conference, Sept. 14-16, 2026, in New York, showcasing the company's work to overcome cancer drug resistance. #Oncology #Biopharma
@drtimos.bsky.social🧠 Competitive Insights for #BioPharma and #HealthTech 🚀
#LucidQuest arms #pharma & #biotech with real-time intel to outpace rivals from R&D to market.
📩 [email protected] or http://dlvr.it/TVPP0s
#CompetitiveIntelligence #Strategy #MarketAccess
@leeasplund.bsky.socialWelcome to Wednesday Words, where I will define one word used in biotechnology or biopharma each Wednesday morning!
If you want to learn more, check out: sbee.link/j9t7xqpwar
#wednesdaywords #biotechnology #biopharma #IND #ClinicalTrials #science
@newsramp.comTonix Pharmaceuticals (NASDAQ: TNXP) promotes Thomas Englese to Chief Commercial Officer to lead growth of TONMYA, the first new fibromyalgia treatment in 15+ years, plus its migraine portfolio. #Biopharma #TNXP
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) receives FDA clearance to begin a Phase 2 trial of Lucid-MS, a first-in-class drug targeting demyelination in multiple sclerosis. Rodman & Renshaw initiates coverage with a Buy rating and $8 price target. #MultipleSclerosis #Biopharma
@newsramp.comQuantum BioPharma (NASDAQ: QNTM) receives FDA clearance to begin a Phase 2 trial of Lucid-MS, a first-in-class drug targeting demyelination in multiple sclerosis patients. Rodman & Renshaw initiates coverage with a Buy rating and $8 price target. #MultipleSclerosis #Biopharma
